The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study

[1]  R. S. Soares Magalhaes,et al.  The Association Between the Use of Oclacitinib and Antibacterial Therapy in Dogs With Allergic Dermatitis: A Retrospective Case-Control Study , 2021, Frontiers in Veterinary Science.

[2]  K. Gortel.  Twenty years of pyodermas: How antimicrobial resistance has changed the way I practice. , 2020, The Canadian veterinary journal = La revue veterinaire canadienne.

[3]  A. Gonzales,et al.  Update on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs. , 2019, Journal of the American Veterinary Medical Association.

[4]  D. Santoro.  Therapies in Canine Atopic Dermatitis: An Update. , 2019, The Veterinary clinics of North America. Small animal practice.

[5]  Publisher's Note , 2018, Anaesthesia.

[6]  H. Moyaert,et al.  A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client‐owned dogs with atopic dermatitis , 2017, Veterinary dermatology.

[7]  Timothy Baldwin,et al.  VetCompass Australia: A National Big Data Collection System for Veterinary Science , 2017, Animals : an open access journal from MDPI.

[8]  T. Olivry,et al.  Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA) , 2015, BMC Veterinary Research.

[9]  Domenico Santoro,et al.  Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification , 2015, BMC Veterinary Research.

[10]  M. Stegemann,et al.  Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. , 2015, Veterinary dermatology.

[11]  M. Stegemann,et al.  A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs , 2014, Veterinary dermatology.

[12]  M. Stegemann,et al.  Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia , 2014, Veterinary dermatology.

[13]  J. Weese,et al.  Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). , 2014, Veterinary dermatology.

[14]  J. Tena,et al.  A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client‐owned dogs with atopic dermatitis , 2013, Veterinary dermatology.

[15]  J. Boucher,et al.  Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis , 2013, Veterinary dermatology.

[16]  T. Olivry,et al.  Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. , 2010, Veterinary dermatology.

[17]  D. Mellor,et al.  Adherence by Staphylococcus intermedius to canine corneocytes: a preliminary study comparing noninflamed and inflamed atopic canine skin. , 2006, Veterinary dermatology.